Table I.

Characteristics of the new oral anticoagulants.

Characteristics	Direct thrombin inhibitor	Factor Xa inhibitors
	Dabigatran	Apixaban	Edoxaban	Rivaroxaban
Prodrug	Yes	No	No	No
Bioavailability (%)	3–7	50	62	80
Time to peak concentration (hours)	1–3	1–3	1–3	2–4
Half-life (hours)	12–17	8–15	8–10	7–13
Renal clearance (%)	80	25	35	36
Elimination	Urine and faeces	Urine and faeces	Urine and faeces	Urine and faeces
Dosing regimen	110–150 mg twice daily	2.5–5 mg twice daily	15–30 mg once daily	10–30 mg once daily
Metabolism	P-glycoprotein	P-glycoprotein, CYP3A4	P-glycoprotein, CYP3A4	P-glycoprotein, CYP3A4
Antidotes under development	Idarucizumab, modified thrombin molecules	Andexanet alfa, Aripazine	Andexanet alfa, Aripazine	Andexanet alfa, Aripazine